|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on September 12, 2002; DOI 10.1182/blood-2002-05-1592.
NEOPLASIA
From the Center for Human Genetics, Catholic University
of Leuven, Leuven, Belgium; the Department of Pathology, Stichting
PAMM, Eindhoven, the Netherlands; the Division for Morphology and
Molecular Pathology, Catholic University of Leuven, Leuven, Belgium;
and the Institute of Human Genetics, University Hospital, Kiel,
Germany.
We studied the genomic status of BCL6 in 23 cases of
nodular lymphocyte predominance Hodgkin lymphoma (NLPHL) and 40 cases of classical Hodgkin lymphoma (cHL), using dual-color interphase fluorescence in situ hybridization (FISH). The BCL6
rearrangement was identified in 48% of NLPHL cases and was not
detected in cHL cases. As a confirmation, sequential or simultaneous
immunohistochemistry (IHC) and FISH using CD20 or BCL6
antibodies and BCL6 DNA probes was performed in 8 NLPHL
cases. The BCL6-associated translocations, t(3;22)(q27;q11), t(3;7)(q27;p12), and the most probable
t(3;9)(q27;p13), were identified in 3 cases. A consistent
expression of BCL6 protein in popcorn cells with the highest number of
intensely stained cells in cases with a genomic BCL6
rearrangement was shown by IHC. These findings support the hypothesis
of a germinal center B cell-derived origin of NLPHL, indicate a
significant role of BCL6 in the pathogenesis of NLPHL, and
provide further evidence of the genetic diversity underlying the
pathogenesis of NLPHL and cHL.
(Blood. 2003;101:706-710) On the basis of morphologic, immunohistochemical,
and clinical features, 2 distinct biologic entities of Hodgkin lymphoma (HL) have been recognized: nodular lymphocyte predominance HL (NLPHL)
and classical HL (cHL).1,2 Several lines of evidence indicate that the neoplastic cells of HL originate from a germinal center (GC) B cell that has been selected and stimulated by
antigen.3-8 Accordingly, immunohistochemical studies
showed that neoplastic cells of NLPHL (popcorn cells) were consistently
associated with a BCL6+/CD138 The BCL6 protein regarded as a GC marker12-14 is a
multifunctional regulator of lymphocyte differentiation and immune
response (for reviews, see Staudt et al15 and
Ye16). The gene encoding BCL6 located at 3q27 is a
frequent target of promiscuous chromosomal translocations found in
approximately 1 of 6 malignant lymphomas, mainly of a diffuse large
B-cell type.15,17-19 At the molecular level, all
BCL6-associated translocations lead to up-regulation of
BCL6 transcription by a mechanism of promoter
exchange,20,21 probably preventing down-regulation of its
transcription that occurs upon plasmacytic differentiation.
Molecular mechanisms and genes that play key roles in the
pathogenetic pathways underlying the neoplastic process in HL remain largely unknown. Following up on our recent finding of
BCL6 rearrangement in 2 NLPHL cases,22 we
studied the genomic status of BCL6 in a series of
cases diagnosed as NLPHL and cHL, using dual-color interphase fluorescence in situ hybridization (FISH).
Patient material
G-banding analysis
FISH analysis FISH analysis of the BCL6 gene was performed with the Locus Specific Identifiers (LSI) BCL6 Dual Color, Break Apart Rearrangement Probe (Vysis, Bergisch-Gladbach, Germany) according to the manufacturer's instructions. The FISH data were collected on a Leica DMRB fluorescence microscope (Leica, Wetzlar, Germany) equipped with a cooled black-and-white charged-couple-device camera (Photometrics, Tuscon, AZ) run by Quips SmartCapture FISH Imaging Software (Vysis).Immunohistochemistry (IHC) Immunostaining for BCL6 was performed on formalin-fixed, paraffin-embedded sections with the UltraVision detection system (Lab Vision, Fremont, CA) and the BCL6 antibody (Ab-1, mouse monoclonal antibody Clone P1F6, Neomarkers, Fremont, CA; and PG-Bp6, DAKO, Glostrub, Denmark).Results of the interphase FISH analysis were validated by sequential IHC and FISH analysis or combined immunophenotyping and interphase cytogenetics (FICTION) analysis applied on frozen tissue sections (10 µm) from, respectively, 4 (nos. 1, 3-5) and 4 (nos. 13-16) NLPHL cases. In the first approach, CD20 (L26; DAKO) immunostained frozen tissue sections were reviewed and popcorn cells were localized and recorded. Subsequently, these sections were subjected to BCL6-FISH and the previously recorded cells were evaluated. FICTION with CD20 and LSI BCL6 was performed according to the previously described protocol.24
Initially, metaphase and interphase cells from 2 previously
reported NLPHL cases22 with structural aberrations of 3q27
identified as the t(3;22)(q27;q11) (case 1) and the complex der 3 t(3;?;1) (3pter
In the remaining 21 NLPHL cases and 40 cHL cases without available chromosome spreads, LSI BCL6 FISH studies were performed on an interphase cell level. Only large atypical nuclei were evaluated. The number of atypical cells analyzed in each specimen ranged from 6 to 35, with an average of 11 and 16 in NLPHL and cHL samples, respectively. FISH patterns indicative of the BCL6 rearrangement were found in 9 NLPHL cases, which together with the 2 previously presented cases indicates an occurrence of BCL6-R in 48% (11 of 23) of NLPHL cases. Results of interphase FISH showed that atypical cells identified in cases with BCL6-R displayed different configurations of fused (germ line BCL6) as well as split green and orange signals (rearranged BCL6; Table 1). Balanced green and orange signals indicative of a reciprocal BCL6 translocation were found in 7 samples (cases 1, 3-5, 13, 15a, and 16; Figure 1A-B,E,F inset,G inset). In 6 samples (cases 2, 6, 14, 15b, 17a, and 17b), we observed either loss of the orange or green signal, suggesting a nonreciprocal translocation, or presence of an extra green signal, likely due to a duplication of the der 3 or the 3' end of BCL6, as detected in case 2 (Figure 1D). Most analyzed cases showed a cell-to-cell variation of the number of signals, most probably reflecting different ploidy levels (ranging from 2n to 8n). Of interest, 2 patients (cases 3 and 6) later developed a BCL6-associated DLBCL. In case 3, a t(3;9)(q27;p13) was identified on metaphases of DLBCL and was retrospectively shown by FISH to be present in NLPHL (I.W. et al, in preparation). Large atypical cells from the remaining 12 NLPHL cases showed the presence of numerous fused FISH signals indicative of a BCL6 germ line configuration (data not shown). The number of signals per cell varied and ranged from 2 to 12, but in 6 and 2 cases predominant cell clones with 3 and 4 fusion signals, respectively, were evident. The validity of the applied approach (FISH analysis of selected large atypical nuclei) was confirmed by performing either a sequential IHC and FISH with CD20 and LSI BCL6 (on samples 1 and 3-5) or FICTION (on samples 13, 14, 15a, 15b, and 16) on frozen tissue sections from 9 BCL6-R NLPHL cases, respectively. In each of these cases, 4 to 25 informative popcorn cells selected by morphologic criteria were evaluated, and all of them showed fused as well as split green and orange signals (examples are shown in Figure 1E-F,F inset). The reliability of our results is also supported by a finding of a similar incidence of BCL6-R in NLPHL cases coming from 2 different centers (Leuven, 6 of 12; Eindhoven, 5 of 11). To check whether genomic rearrangements of BCL6 were
reflected at the protein level, we analyzed 11 available NLPHL cases, using immunostaining with anti-BCL6 antibody. Assessment of BCL6 immunostaining was carried out blindly in 100 popcorn cells per case
without knowledge of the BCL6 gene status. Popcorn cells showed expression of BCL6 in all cases, but the number of positive cells as well as the intensity of immunostaining varied. The
percentages of BCL6+ cells ranged from 40% to 97% and
were assigned to the following categories: less than 50%, 50% to
75%, and more than 75%. These categories comprised 2, 2, and 7 cases,
respectively (Table 2). Of note, the
highest percentages of BCL6-positive popcorn cells (ranging from 87%
to 97%) and the strongest BCL6 immunostaining were observed in 5 NLPHL
cases with a rearrangement of BCL6. These findings are
illustrated by a sequential anti-BCL6/BCL6-FISH analysis additionally performed in cases 1 (Figure 1G,G inset) and 3. Taken together, our observations confirmed previous findings of a common expression of BCL6 in popcorn cells9,10 and, in addition, showed that at least in some NLPHL cases a strong expression of BCL6
may result from a genomic rearrangement of the BCL6 gene affected by chromosomal translocations.
Comparison of BCL6 alterations in NLPHL with those reported for DLBCL showed striking similarities. Both lymphoma types showed a similar frequency of BCL6 rearrangements (more than 40% of cases), occurrence of the same type of translocations (eg, t(3;22), t(3;7), t(3;9)) involving either Ig or non-Ig loci, and a common expression of BCL6 protein. A relationship between the 2 lymphomas was illustrated in 2 patients (nos. 3 and 6), who presented consecutively NLPHL and DLBCL. These findings further support a GC B cell-derived origin of popcorn cells and indicate that genomic rearrangements of BCL6 may play an important role in the initiation of NLPHL, just as they do in DLBCL. The finding of frequent BCL6 rearrangement in NLPHL remains in contrast with results obtained in cHL. This latter group comprised 23 cases of nodular sclerosis (NS) HL and 17 cases of mixed-cellularity (MC) HL. Atypical cells from all 40 cases analyzed by interphase FISH showed the presence of numerous fused (but not split) LSI BCL6 signals, pointing to the germ line BCL6 gene (an example is shown in Figure 1C). The difference in the frequency of BCL6 breaks in NLPHL versus cHL is highly significant (P < .001 by Fisher exact test). As in NLPHL, the number of signals per cell in cHL cases varied and ranged from 2 to 16, most likely reflecting the genomic instability of HL-related neoplastic cells, previously reported by other groups.24,28-31 In summary, we show here the frequent occurrence of BCL6 rearrangement in NLPHL, which was detected by FISH in 11 (48%) of 23 analyzed cases, but not in NS and MC subtypes of cHL (0 of 40 cases; P < .001, Fisher exact test). These findings remain in agreement with immunohistochemical data showing consistent expression of BCL6 in NLPHL and lack of or low-level expression of BCL6 in RS cells9,10 and reinforce the concept of distinct, entity-related mechanisms of pathogenesis in these tumors.
We thank Ursula Pluys and Rens van Hezik for skillful technical assistance, Emina Torlakovic for double-checking the BCL6 immunostaining, and Rita Logist for editorial help. These research results are from the Interuniversity Poles of Attraction program initiated by the Belgian Prime Minister's Office, Science Policy Programming. All scientific responsibility is assumed by the authors.
Submitted May 29, 2002; accepted August 21, 2002.
Prepublished online as Blood First Edition Paper, September 12, 2002; DOI 10.1182/blood-2002-05-1592.
Supported by grant G025298 from the Fund for Scientific Research (FWO), Flanders, Belgium, and by the Interdisiziplinäres Zentrum für Klinische Krebsforschung (IZKF), Kiel, Germany.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Anne Hagemeijer, Center for Human Genetics, University of Leuven, Campus Gasthuisberg O&N6, Herestraat 49, B-3000 Leuven, Belgium; e-mail: anne.hagemeijer{at}med.kuleuven.ac.be.
1.
Harris NL, Jaffe ES, Stein H, et al.
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
Blood.
1994;84:1361-1392 2. Jaffe E, Harris NL, Stein H, Vardiman JW. Tumors of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumors. Lyon, France: IARC Press; 2001. 3. Kuppers R, Roers A, Kanzler H. Molecular single cell studies of normal and transformed lymphocytes. Cancer Surv. 1997;30:45-58[Medline] [Order article via Infotrieve].
4.
Braeuninger A, Kuppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML.
Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells.
Proc Natl Acad Sci U S A.
1997;94:9337-9342
5.
Brauninger A, Hansmann ML, Strickler JG, et al.
Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma.
N Engl J Med.
1999;340:1239-1247
6.
Marafioti T, Hummel M, Anagnostopoulos I, et al.
Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells.
N Engl J Med.
1997;337:453-458
7.
Marafioti T, Hummel M, Foss HD, et al.
Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.
Blood.
2000;95:1443-1450
8.
Cossman J, Annunziata CM, Barash S, et al.
Reed-Sternberg cell genome expression supports a B-cell lineage.
Blood.
1999;94:411-416
9.
Falini B, Bigerna B, Pasqualucci L, et al.
Anagnastopoulos I, Dalla-Favera R, Flenghi L. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease.
Blood.
1996;87:465-471
10.
Carbone A, Gloghini A, Gaidano G, et al.
Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease.
Blood.
1998;92:2220-2228
11.
Falini B, Mason DY.
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry.
Blood.
2002;99:409-426
12.
Cattoretti G, Chang CC, Cechova K, Zhang J, et al.
BCL-6 protein is expressed in germinal-center B cells.
Blood.
1995;86:45-53
13.
Onizuka T, Moriyama M, Yamochi T, et al.
BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts.
Blood.
1995;86:28-37 14. Flenghi L, Bigerna B, Fizzotti M, et al. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. Am J Pathol. 1996;148:1543-1555[Abstract]. 15. Staudt LM, Dent AL, Shaffer AL, Yu X. Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6. Int Rev Immunol. 1999;18:381-403[Medline] [Order article via Infotrieve]. 16. Ye BH. BCL-6 in the pathogenesis of non-Hodgkin's lymphoma. Cancer Invest. 2000;18:356-365[Medline] [Order article via Infotrieve].
17.
Bastard C, Deweindt C, Kerckaert JP, et al.
LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients.
Blood.
1994;83:2423-2427
18.
Lo CF, Ye BH, Lista F, et al.
Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma.
Blood.
1994;83:1757-1759
19.
Otsuki T, Yano T, Clark HM, et al.
Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences.
Blood.
1995;85:2877-2884 20. Ye BH, Chaganti S, Chang CC, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J. 1995;14:6209-6217[Abstract].
21.
Chen W, Iida S, Louie DC, Dalla-Favera R, Chaganti RS.
Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation.
Blood.
1998;91:603-607
22.
Franke S, Wlodarska I, Maes B, et al.
Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances.
Blood.
2001;97:1845-1853 23. Mitelman F, ed. ISCN. An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
24.
Martin-Subero JI, Gesk S, Harder L, et al.
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.
Blood.
2002;99:1474-1477
25.
Miki T, Kawamata N, Arai A, et al.
Molecular cloning of the breakpoint for 3q27 translocation in B-cell lymphomas and leukemias.
Blood.
1994;83:217-222 26. Ichinohasama R, Miura I, Funato T, et al. A recurrent nonrandom translocation (3;7)(q27;p12) associated with BCL6 gene rearrangement in B-cell diffuse large cell lymphoma. Cancer Genet Cytogenet. 1998;104:19-27[CrossRef][Medline] [Order article via Infotrieve].
27.
Hosokawa Y, Maeda Y, Ichinohasama R, Miura I, Taniwaki M, Seto M.
The Ikaros gene, a central regulator of lymphoid differentiation, fuses to the BCL6 gene as a result of t(3;7)(q27;p12) translocation in a patient with diffuse large B-cell lymphoma.
Blood.
2000;95:2719-2721
28.
Weber-Matthiesen K, Deerberg J, Poetsch M, Grote W, Schlegelberger B.
Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease.
Blood.
1995;86:1464-1468 29. Nolte M, Werner M, von Wasielewski R, Nietgen G, Wilkens L, Georgii A. Detection of numerical karyotype changes in the giant cells of Hodgkin's lymphomas by a combination of FISH and immunohistochemistry applied to paraffin sections. Histochem Cell Biol. 1996;105:401-404[Medline] [Order article via Infotrieve]. 30. Pringle JH, Shaw JA, Gillies A, Lauder I. Numerical chromosomal aberrations in Hodgkin's disease detected by in situ hybridisation on routine paraffin sections. J Clin Pathol. 1997;50:553-558[Abstract]. 31. Jansen MP, Hopman AH, Haesevoets AM, et al. Chromosomal abnormalities in Hodgkin's disease are not restricted to Hodgkin/Reed-Sternberg cells. J Pathol. 1998;185:145-152[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. I. Martin-Subero, W. Klapper, A. Sotnikova, E. Callet-Bauchu, L. Harder, C. Bastard, R. Schmitz, S. Grohmann, J. Hoppner, J. Riemke, et al. Chromosomal Breakpoints Affecting Immunoglobulin Loci Are Recurrent in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin Lymphoma Cancer Res., November 1, 2006; 66(21): 10332 - 10338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Chen, X.-T. Hu, A. C. Liang, W.-Y. Au, C.-C. So, M. L. Wong, L. Shen, Q. Tao, K.-M. Chu, Y.-L. Kwong, et al. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma Blood, October 1, 2006; 108(7): 2373 - 2383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Liso, D. Capello, T. Marafioti, E. Tiacci, M. Cerri, V. Distler, M. Paulli, A. Carbone, G. Delsol, E. Campo, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma Blood, August 1, 2006; 108(3): 1013 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Re, R. Kuppers, and V. Diehl Molecular Pathogenesis of Hodgkin's Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6379 - 6386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Renne, J. I. Martin-Subero, M.-L. Hansmann, and R. Siebert Molecular Cytogenetic Analyses of Immunoglobulin Loci in Nodular Lymphocyte Predominant Hodgkin's Lymphoma Reveal a Recurrent IGH-BCL6 Juxtaposition J. Mol. Diagn., August 1, 2005; 7(3): 352 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Poppema Immunobiology and Pathophysiology of Hodgkin Lymphomas Hematology, January 1, 2005; 2005(1): 231 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Katzenberger, G. Ott, T. Klein, J. Kalla, H. K. Muller-Hermelink, and M. M. Ott Cytogenetic Alterations Affecting BCL6 Are Predominantly Found in Follicular Lymphomas Grade 3B with a Diffuse Large B-Cell Component Am. J. Pathol., August 1, 2004; 165(2): 481 - 490. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
phenotype
typical of GC cells. The phenotype of Reed-Sternberg (RS) cells of cHL
(mostly BCL6
20°C were available for FISH analysis. In the
11 NLPHL cases (nos. 13-23) not previously subjected to cytogenetic
analysis, the interphase FISH was performed either on tissue imprints
and/or single cells isolated from frozen tissue sections or on frozen
tissue sections. In 2 cases (nos. 15 and 17), consecutive biopsies
obtained at time of relapse were additionally examined (a indicates
original samples; b, relapsed samples).
3q27::?::1q21
(Ig
